
AOD-9604
AOD-9604 failed as an obesity drug: in the company's largest trial, oral doses for 24 weeks did not cause significant weight loss versus placebo, and development ended in 2007. FDA reviewed it in 2024 and found a lack of evidence of effectiveness for obesity by any route and insufficient safety information, and its advisory committee voted 12 to 0 against allowing it in pharmacy compounding. Claims about cartilage, joints, bones or anti-aging rest on animal or no data.
Research compound: not an approved drug or dietary supplement
This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only. Talk to a clinician before considering it.
Quick decision guide
May help most
No approved or proven use
Common dosing range
No approved or established dose. Company trials, as summarized by FDA, tested oral doses of 0.25 to 30 mg a day for up to 24 weeks (higher doses only in short studies); FDA found no human data for injections under the skin, the form sold today
When to expect effects
No meaningful effect shown in people
Watch out for
Not FDA-approved; failed its obesity trials; FDA found limited safety data, no human data for injections, and cancer reports in one trial it could not resolve; it is on WADA's prohibited list according to FDA's review; online and clinic products are unverified
What is it
AOD-9604 is a lab-made peptide based on the tail end of human growth hormone (amino acids 177 to 191, with an extra tyrosine added). The Australian company Metabolic Pharmaceuticals developed it in the late 1990s as a pill for obesity, and stopped in February 2007 after its largest trial (502 randomized adults with obesity, 24 weeks) did not show significant weight loss compared with placebo. It is not FDA-approved, and FDA's 2024 review found no monograph for it in the major pharmacopeias of Europe, China, India or Japan. On December 4, 2024, after FDA proposed that it not be included, FDA's Pharmacy Compounding Advisory Committee voted 0 yes and 12 no on placing AOD-9604 on the list of bulk substances pharmacies may use in compounding under section 503A, and FDA now lists it among substances once in category 2 (may present significant safety risks) whose nominations were withdrawn. It is still marketed by clinics, med spas and online sellers, mostly as injections, a route FDA found no human data for.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
fat breakdown and weight gain in obese mice and rats Mixed Evidence | Weight gain cut by more than half in obese rats; no significant weight loss in human trials | None in people | 2 to 3 weeks in rodents |
cartilage repair in a rabbit model of knee osteoarthritis Mixed Evidence | Better cartilage scores than saline in rabbits | None in people | Measured at 8 weeks in rabbits |
fat breakdown and weight gain in obese mice and rats
- Effect
- Weight gain cut by more than half in obese rats; no significant weight loss in human trials
- Best fit
- None in people
- Time
- 2 to 3 weeks in rodents
cartilage repair in a rabbit model of knee osteoarthritis
- Effect
- Better cartilage scores than saline in rabbits
- Best fit
- None in people
- Time
- Measured at 8 weeks in rabbits
Evidence for 2 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
fat breakdown and weight gain in obese mice and rats
Mechanism onlyIn obese mice given AOD-9604 by pump for 14 days, weight gain was lower, fat burning and fat breakdown increased, and, unlike full growth hormone, blood sugar did not rise; AOD-9604 did not bind the growth hormone receptor. In obese Zucker rats, a daily oral dose of 500 micrograms per kg for 19 days cut weight gain by more than half (15.8 versus 35.6 g). These are animal results and have not been shown in people. Separately, FDA's 2024 briefing document for its Pharmacy Compounding Advisory Committee reports that in most of the human studies it identified, AOD-9604 did not beat placebo for weight loss, including the largest trial (502 randomized adults with obesity, 24 weeks, with diet and exercise), which missed its primary endpoint at 12 weeks.
Bottom line: It slowed weight gain in rodents, but failed to cause meaningful weight loss in human trials.
cartilage repair in a rabbit model of knee osteoarthritis
Mechanism onlyIn 32 rabbits with knee damage induced by an enzyme, weekly injections of AOD-9604 into the knee (weeks 4 to 7) led to better cartilage scores and shorter lameness than saline, and the combination with hyaluronic acid did better than either alone. This has never been tested in people: FDA's 2024 review found no clinical studies of AOD-9604 for osteoarthritis or osteoporosis, and the rabbit study used injections into the joint, not the under-the-skin injections sellers promote.
Bottom line: A single rabbit study; there is no human evidence for joints or cartilage.
How it works
How to take it
What to track
Bottom line: There is no dose that has been shown to work, and the injected form was never tested in people.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Cancers reported in a trial. In a 12-week company trial of 300 adults with obesity (oral AOD-9604 at one of five doses or placebo, 50 per group), serious adverse events included basal cell carcinoma, squamous cell carcinoma, breast cancer, malignant melanoma and a lipoma. The investigators judged them unrelated, but FDA wrote that it has concerns about these reports and that "information is insufficient whether these various types of cancers were unrelated to AOD-9604."
Other serious or severe events in trials: diarrhea (serious, possibly related) at an oral dose of 54 mg, and a severe feeling of chest tightness after an intravenous dose, judged possibly related. FDA's compounding safety summary says it identified serious adverse events that may be associated with AOD-9604, though causality is not clear.
No human data for injections, and possible immune reactions. FDA found no human data for AOD-9604 injected under the skin or applied to the skin, and no pharmacokinetic data for any route. As a 16-amino-acid peptide it may trigger immune reactions, especially when injected, and FDA found it not well characterized, with endotoxin testing lacking for injectable products.
Animal and lab signals. In long-term oral studies, rats showed changes in a bone-turnover marker (osteocalcin) and monkeys showed minimal liver cell changes; genetic toxicity tests gave unclear (equivocal) results. FDA said these findings suggest clinically relevant safety signals may develop, and that the studies were too limited to judge safety. No reproductive or cancer studies in animals were identified.
Unknown long-term safety. FDA concluded there is insufficient information to support safety for long-term use, which obesity treatment would require.
Who should avoid it
- Anyone considering injections or creams: FDA found no human data for these routes
- People with a history of cancer, given the unresolved cancer reports in one trial
- Athletes tested under anti-doping rules: FDA's review notes AOD-9604 is on the World Anti-Doping Agency's prohibited list (section S2.2) and has been found in vials from athletes
- People with obesity looking for treatment: FDA's review notes there are multiple FDA-approved weight-management medicines, while AOD-9604 lacks evidence of effectiveness
Pregnancy & breastfeeding
There are no human data on AOD-9604 in pregnancy or breastfeeding, and FDA's 2024 review identified no animal studies of its effects on reproduction or development. Avoid use if you are pregnant, breastfeeding or planning a pregnancy, and talk to your doctor.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is AOD-9604 FDA-approved?⌄
No. No AOD-9604 product is approved by FDA. It was developed as an obesity pill in Australia, and development stopped in 2007 after its largest trial did not show significant weight loss.
Does AOD-9604 work for weight loss?⌄
The evidence says no. According to FDA's 2024 review, most of the company's trials did not show weight loss beyond placebo; one 12-week trial, reported only in a meeting abstract, claimed small differences that FDA said have unclear meaningful therapeutic effects. Its largest trial (502 randomized adults with obesity, 24 weeks, with a diet and exercise program) missed its main goal. FDA concluded there is a lack of evidence of effectiveness for obesity by any route. Ask your doctor about approved weight-management options.
Can a compounding pharmacy legally make AOD-9604?⌄
On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 0 yes and 12 no on placing AOD-9604 on the list of bulk substances that pharmacies may use under section 503A, after FDA proposed not adding it. FDA's compounding safety page now lists AOD-9604 among substances previously in category 2 whose nominations were withdrawn. Compounded drugs are not FDA-approved and are not checked by FDA for safety or quality.
Is AOD-9604 the same as growth hormone?⌄
No. It is a small piece of the growth hormone molecule with an added amino acid. In lab studies it did not bind the growth hormone receptor, and in company trials it did not change IGF-1 levels. It does not do what growth hormone does.
Is it banned in sport?⌄
FDA's 2024 review notes that AOD-9604 is on the World Anti-Doping Agency's prohibited list under section S2.2, that an Australian Crime Commission report listed it as supplied to athletes, and that it has been found in vials obtained from elite athletes in Germany and Belgium and in confiscated vials in the US.
Can I take AOD-9604 with my supplements or medicines?⌄
No interaction studies exist, and no human data exist for the injected form that is sold today. Products are often sold in combination with other peptides or drugs, which adds unknown risks. A doctor or pharmacist should review your full list.
References by claim
fat breakdown and weight gain in obese mice and rats
cartilage repair in a rabbit model of knee osteoarthritis
Kwon et al., 2015 · PubMed (2015) link
Track AOD-9604 with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research (much of it preclinical or early-stage), not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.
